{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=86",
    "query": {
      "intervention": "Sequence",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 2516,
    "total_pages": 252,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T23:19:47.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01209117",
      "title": "A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Human Immunodeficiency Virus and Herpesviridae",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2248761 WBM Capsule",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 3",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209117"
    },
    {
      "nct_id": "NCT05134415",
      "title": "Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Electronic Cigarette Use"
      ],
      "interventions": [
        {
          "name": "RELX ENDS Tobacco Flavor 1",
          "type": "OTHER"
        },
        {
          "name": "RELX ENDS Tobacco Flavor 2",
          "type": "OTHER"
        },
        {
          "name": "RELX ENDS Menthol Flavor 1",
          "type": "OTHER"
        },
        {
          "name": "RELX ENDS Menthol Flavor 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Cheerain HK Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-10-12",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Burbank, California",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05134415"
    },
    {
      "nct_id": "NCT03584425",
      "title": "Imaging Laterality in Chronic Stroke Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stroke",
        "Motor Cortex; Lesion"
      ],
      "interventions": [
        {
          "name": "Rasch modified version of the Fugl-Meyer Motor assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Anatomical image acquisition",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Functional MRI task and acquisition",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 44,
      "start_date": "2014-12-15",
      "completion_date": "2019-05-30",
      "has_results": false,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03584425"
    },
    {
      "nct_id": "NCT05455502",
      "title": "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "VX-548",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-07-13",
      "completion_date": "2022-09-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05455502"
    },
    {
      "nct_id": "NCT00423761",
      "title": "An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "GW876008",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-05-18",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423761"
    },
    {
      "nct_id": "NCT02933073",
      "title": "Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "OncoImmunome",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UConn Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2016-11",
      "completion_date": "2022-08",
      "has_results": false,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02933073"
    },
    {
      "nct_id": "NCT02895945",
      "title": "BAX 802 in CHA With Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "12 Years to 75 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2016-12-22",
      "completion_date": "2021-01-22",
      "has_results": true,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 3,
      "location_summary": "Peoria, Illinois • Winston-Salem, North Carolina • Cleveland, Ohio",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02895945"
    },
    {
      "nct_id": "NCT01873339",
      "title": "Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Darapladib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2013-06-19",
      "completion_date": "2013-09-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873339"
    },
    {
      "nct_id": "NCT07813039",
      "title": "A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-581",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2026-09-23",
      "completion_date": "2026-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07813039"
    },
    {
      "nct_id": "NCT03180853",
      "title": "Multiple Myeloma Patient Registry",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-05-08",
      "completion_date": "2018-04-06",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-11-14T23:19:47.243Z",
      "location_count": 69,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 63 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03180853"
    }
  ]
}